Limoges Cedex 1

• Clinical trial to assess the safety and tolerability of TP-122A for the treatment of ventilator-associated pneumonia. Not authorised
  2023-508825-29-00 7 Ventilator-Associated Pneumonia
• SPARE : Stopping Pneumonia Antibiotherapy Regimen Early Pending
  2024-512236-30-00 5 Community-acquired alveolar pneumonia in children
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 5 Multiple Myeloma
• Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas … Pending
  2024-515362-13-00 10 Philadelphia-negative myeloproliferative neoplasms are frequent and ch
• A multi-center open-label phase 2 study of Ixazomib, Iberdomide and dexamethasone in elderly patients with multiple myeloma at first relapse Pending
  2024-516257-44-00 4 Multiple myeloma
• CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) P … Pending
  2024-516328-32-00 4 CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
• Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study Pending
  2024-516335-27-00 5 anti-MAG neuropathy
• A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP … Pending
  2024-516570-30-00 4 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
• Efficacy and safety of circumcision alone on risk of febrile urinary tract infections in boys with posterior urethral valves: a prospective … Pending
  2024-519166-48-01 4 Posterior Urethral Valves
• Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending
  2024-519624-24-00 4 HER3-mutant and HER2-not amplified metastatic breast cancer
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending
  2024-519753-11-00 4 Resectable borderline pancreatic adenocarcinoma
• BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance Pending
  2025-521093-34-00 5 rare disease
• MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending
  2025-521331-36-00 10 Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
• PREV-CART - “A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiot … Pending
  2025-521571-30-00 5 Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (
• Usnoflast Neuromuscular Investigation for Treatment Efficacy in ALS (UNITE-ALS) Pending
  2025-522580-15-00 4 Amyotrophic Lateral Sclerosis (ALS)
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or … Pending
  2025-523461-17-01 5 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant … Pending
  2025-524241-27-00 5 Treatment-naїve mantle cell lymphoma (MCL)
• Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial Pending
  2025-524297-42-00 5 CLTI defined as Rutherford category 4 or 5
• Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kid … Recruiting
  2024-516527-13-00 11 2026-05-27 Kidney transplantation
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation

Showing 1–24 of 190 trials